Venetoclax-obinutuzumab combination elicits high response rates in CLL

Previously untreated patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions who received fixed-duration venetoclax plus obinutuzumab had better survival outcomes compared with fixed-duration chemoimmunotherapy, showed results from the international, open-label, phase 3 CLL14 trial [1, 2]. Dr Kirsten Fischer (University of Cologne, Germany) presented the CLL14 trial. The trial included 432 previously untreated patients with CLL and coexisting conditions, and patients were randomly assigned treatment with fixed-duration venetoclax plus obinutuzumab (n=216) or fixed-duration chlorambucil plus obinutuzumab (n=216). Venetoclax rapidly induces apoptosis of CLL by selective inhibition of BCL2, a protein that regulates cell death and is overexpressed in CLL cells. Obinutuzumab is an anti-CD20 monoclonal antibody that is able...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 9 June, 201911 March, 2021